Expert opinion on drug metabolism & toxicology最新文献_第9页

Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson's disease. 治疗帕金森病的左旋多巴和相关附加疗法的临床药代动力学。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-11-11 DOI: 10.1080/17425255.2024.2428831

Thomas Müller

{"title":"Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson's disease.","authors":"Thomas Müller","doi":"10.1080/17425255.2024.2428831","DOIUrl":"https://doi.org/10.1080/17425255.2024.2428831","url":null,"abstract":"Introduction: Parkinson's disease is a chronic neurodegenerative disease entity characterized by heterogeneity of symptoms and progression. Levodopa is an efficacious and well tolerated dopamine substituting drug for its therapy. Its O-methylation and generation of 3-O-methyldopa is enhanced by levodopa/dopa decarboxylase inhibitor formulations. Additional inhibition of catechol-O-methyltransferase is the relevant add on therapy for levodopa application. This pharmacologic approach increases the plasma appearance of levodopa and reduces 3-O-methyldopa synthesis. Available marketed compounds are entacapone, tolcapone and opicapone. Data on their effects on levodopa pharmacokinetics in patients are rare.Areas covered: This review describes the impact of this add-on therapy on the pharmacokinetic profile of levodopa and 3-O-methyldopa in plasma. The rationale was to perform a comparison with data from previously published pharmacokinetic trials with a standardized one time intake of levodopa/carbidopa without and with the available catechol-O-methyltransferase inhibitors.Expert opinion: Results of this analysis identified opicapone as the most efficacious inhibitor of catechol-O-methyltransferase in terms of changes of levodopa plasma concentrations. Opicapone induced higher levodopa plasma levels compared with the ones following application of levodopa/carbidopa alone or combined with entacapone or tolcapone. Co-administration of opicapone with its once daily intake regimen may support the efficacy of subcutaneous and intrajejunal levodopa infusions.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity. 体外神经毒性测试：从化疗引起的外周神经毒性中汲取教训。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-11-01 Epub Date: 2024-09-10 DOI: 10.1080/17425255.2024.2401584

Olga Tarasiuk, Chiara Invernizzi, Paola Alberti

{"title":"In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity.","authors":"Olga Tarasiuk, Chiara Invernizzi, Paola Alberti","doi":"10.1080/17425255.2024.2401584","DOIUrl":"10.1080/17425255.2024.2401584","url":null,"abstract":"Introduction: Chemotherapy induced peripheral neurotoxicity (CIPN) is a long-lasting, or even permanent, late toxicity caused by largely used anticancer drugs. CIPN affects a growing population of cancer survivors and diminishes their quality of life since there is no curative/preventive treatment. Among several reasons for this unmet clinical need, there is an incomplete knowledge on mechanisms leading to CIPN. Therefore, bench side research is still greatly needed: in vitro studies are pivotal to both evaluate neurotoxicity mechanisms and potential neuroprotection strategies.Areas covered: Advantages and disadvantages of in vitro approaches are addressed with respect to their applicability to the CIPN field. Different cell cultures and techniques to assess neurotoxicity/neuroprotection are described. PubMed search-string: (chemotherapy-induced) AND (((neuropathy) OR neurotoxicity) OR neuropathic pain) AND (in vitro) AND (((((model) OR SH-SY5Y) OR PC12) OR iPSC) OR DRG neurons); (chemotherapy-induced) AND (((neuropathy) OR neurotoxicity) OR neuropathic pain) AND (model) AND (((neurite elongation) OR cell viability) OR morphology). No articles published before 1990 were selected.Expert opinion: CIPN is an ideal experimental setting to test axonal damage and, in general, peripheral nervous system mechanisms of disease and neuroprotection. Therefore, starting from robust preclinical data in this field, potentially, relevant biological rationale can be transferred to other human spontaneous diseases of the peripheral nervous system.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"1037-1052"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142157044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analgesic medication considerations for chronic pain management post-bariatric surgery. 减肥手术后慢性疼痛治疗的镇痛药物注意事项。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-10-01 Epub Date: 2024-09-10 DOI: 10.1080/17425255.2024.2398631

Sumani Vij, Adriana Too, Victor Tsang, Denise Kreutzwiser

{"title":"Analgesic medication considerations for chronic pain management post-bariatric surgery.","authors":"Sumani Vij, Adriana Too, Victor Tsang, Denise Kreutzwiser","doi":"10.1080/17425255.2024.2398631","DOIUrl":"10.1080/17425255.2024.2398631","url":null,"abstract":"Introduction: Bariatric surgery, an option for obesity management, can significantly alter gastrointestinal structure and processes. These changes can impact the pharmacokinetics (PK) of medications, which can translate to clinical differences in efficacy and safety. Chronic pain is prevalent in obesity and often persists post-bariatric surgery.Areas covered: This narrative review examines the PubMed literature from 1990 to January 2024 for the impact of bariatric surgery on the management of chronic pain medications including non-opioid (acetaminophen, non-steroidal anti-inflammatory drugs, antidepressants, and cannabinoids) and opioid medications.Expert opinion: An individualized medication management approach is ideal for post-bariatric surgery patients, as PK parameters, type of surgery, time since surgery, and patient-specific factors make it difficult to support blanket recommendations. Close monitoring of efficacy and safety outcomes is essential in chronic pain management. While the PK of acetaminophen and opioids are impacted, the value of these medications in the setting of chronic pain is dwindling as more efficacy and safety data emerges. A life-long ban of NSAIDs due to marginal ulcer risk is not endorsed; rather, we advocate for shifting the focus to marginal ulcer prevention strategies, individualized benefit-risk analysis, and safety monitoring using surrogate markers.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"967-976"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142082977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of drug-drug interactions in patients with HIV and metabolic syndrome. 艾滋病毒和代谢综合征患者的药物相互作用分析。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-10-01 Epub Date: 2024-09-10 DOI: 10.1080/17425255.2024.2401044

Jessica Tuan, Grace Igiraneza, Onyema Ogbuagu

{"title":"Analysis of drug-drug interactions in patients with HIV and metabolic syndrome.","authors":"Jessica Tuan, Grace Igiraneza, Onyema Ogbuagu","doi":"10.1080/17425255.2024.2401044","DOIUrl":"10.1080/17425255.2024.2401044","url":null,"abstract":"Background: People with HIV (PWH) are living longer directly related to benefits of highly effective antiretroviral therapy (ART). However, concurrent with improved longevity is the growing prevalence of metabolic comorbidities that drive morbidity and mortality among PWH. There is an increasing repertoire of treatment options for metabolic disorders. Thus, it is important for clinicians to understand the drug-drug interactions (DDIs) between ART and treatments for metabolic disorders.Areas covered: This review will discuss DDIs between contemporary ART and agents used to treat metabolic syndrome (diabetes, dyslipidemia, obesity and hypertension). Literature review of published and unpublished data from manuscripts, conference proceedings, regulatory submissions, and drug prescribing information were conducted from the following sources: PubMed, Google, and Google Scholar through January 2024.Expert opinion: People with HIV have a high prevalence of metabolic disorders. Most significant DDIs between ART and treatments for metabolic disorders are unidirectional with ART as perpetrators, rather than victims, such that careful selection of ART with low DDI propensity can address the concern. However, there are data gaps with DDI data for long-acting ART as well as newer oral and injectable medications for diabetes and weight loss. Nanotechnology-based drug delivery platforms hold promise to address some problematic DDIs.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"953-965"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacokinetics of cefpodoxime: a systematic review. 头孢泊肟的临床药代动力学：系统综述。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-10-01 Epub Date: 2024-08-13 DOI: 10.1080/17425255.2024.2391389

Ayesha Farooq, Ammara Zamir, Imran Imran, Hamid Saeed, Faleh Alqahtani, Anees Ur Rehman, Waseem Ashraf, Muhammad Fawad Rasool

{"title":"Clinical pharmacokinetics of cefpodoxime: a systematic review.","authors":"Ayesha Farooq, Ammara Zamir, Imran Imran, Hamid Saeed, Faleh Alqahtani, Anees Ur Rehman, Waseem Ashraf, Muhammad Fawad Rasool","doi":"10.1080/17425255.2024.2391389","DOIUrl":"10.1080/17425255.2024.2391389","url":null,"abstract":"Introduction: Cefpodoxime, a third-generation cephalosporin, is a broad-spectrum antibiotic widely used to treat acute upper respiratory tract infections (RTI). This systematic review aims to present a comprehensive view of all the available pharmacokinetics (PK) data associated with the pharmacodynamics (PD) parameters of cefpodoxime in humans.Areas covered: The PubMed, Google Scholar, Cochrane Library, and Science Direct, were systematically searched to identify studies on the PK of cefpodoxime. Out of 746 papers, 26 articles meeting the eligibility criteria were included that have reported the PK data. The drug exposure for the patients undergoing hemodialysis was 50% lower than healthy participants. The renal clearance was almost 27% less in pediatric patients than in adults. The plasma concentrations of cefpodoxime exceeded the minimum inhibitory concentration (MIC) for 90% of skin pathogens, including Streptococcus species and Staphylococcus species (i.e.) < 1 μg/mL and 2-4 μg/mL respectively.Expert opinion: The current study includes detailed information on clinical PK of cefpodoxime in healthy, diseased, pediatric populations as well as drug-drug interactions and drug-food interactions. Moreover, this systematic review also explicated PK/PD properties of drug with a specific impact on MIC of drug. The present review will also assist clinicians in the development of PK models for cefpodoxime.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"989-1001"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141908626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma. 肝细胞癌中瑞戈非尼诱发毒性的基本机制和管理策略。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-09-01 Epub Date: 2024-09-03 DOI: 10.1080/17425255.2024.2398628

Mengting Cheng, Xinyu Tao, Fei Wang, Nonger Shen, Zhifei Xu, Yuhuai Hu, Ping Huang, Peihua Luo, Qiaojun He, Yiwen Zhang, Fangjie Yan

{"title":"Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma.","authors":"Mengting Cheng, Xinyu Tao, Fei Wang, Nonger Shen, Zhifei Xu, Yuhuai Hu, Ping Huang, Peihua Luo, Qiaojun He, Yiwen Zhang, Fangjie Yan","doi":"10.1080/17425255.2024.2398628","DOIUrl":"10.1080/17425255.2024.2398628","url":null,"abstract":"Introduction: Hepatocellular carcinoma (HCC) accounts for 85% of liver cancer cases and is the third leading cause of cancer death. Regorafenib is a multi-target inhibitor that dramatically prolongs progression-free survival in HCC patients who have failed sorafenib therapy. However, one of the primary factors limiting regorafenib's clinical utilization is toxicity. Using Clinical Trials.gov and PubMed, we gathered clinical data on regorafenib and conducted a extensive analysis of the medication's adverse reactions and mechanisms. Next, we suggested suitable management techniques to improve regorafenib's effectiveness.Areas covered: We have reviewed the mechanisms by which regorafenib-induced toxicity occurs and general management strategies through clinical trials of regorafenib. Furthermore, by examining the literature on regorafenib and other tyrosine kinase inhibition, we summarized the mechanics of the onset of regorafenib toxicity and mechanism-based intervention strategies by reviewing the literature related to regorafenib and other tyrosine kinase inhibition.Expert opinion: One of the primary factors restricting regorafenib's clinical utilization and combination therapy is its toxicity reactions. To optimize regorafenib treatment regimens, it is especially important to further understand the specific toxicity mechanisms of regorafenib as a multi-kinase inhibitor.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"907-922"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants. 为早产儿咖啡因剂量调整开发和应用群体药代动力学模型库。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-09-01 Epub Date: 2024-08-27 DOI: 10.1080/17425255.2024.2395561

Hao-Ran Dai, Hong-Li Guo, Ya-Hui Hu, Yun Liu, Ke-Yu Lu, Yuan-Yuan Zhang, Jie Wang, Xuan-Sheng Ding, Zheng Jiao, Rui Cheng, Feng Chen

{"title":"Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants.","authors":"Hao-Ran Dai, Hong-Li Guo, Ya-Hui Hu, Yun Liu, Ke-Yu Lu, Yuan-Yuan Zhang, Jie Wang, Xuan-Sheng Ding, Zheng Jiao, Rui Cheng, Feng Chen","doi":"10.1080/17425255.2024.2395561","DOIUrl":"10.1080/17425255.2024.2395561","url":null,"abstract":"Background: Considerable interindividual variability for the pharmacokinetics of caffeine in preterm infants has been demonstrated, emphasizing the importance of personalized dosing. This study aimed to develop and apply a repository of currently published population pharmacokinetic (PopPK) models of caffeine in preterm infants to facilitate model-informed precision dosing (MIPD).Research design and methods: Literature search was conducted using PubMed, Embase, Scopus, and Web of Science databases. Relevant publications were screened, and their quality was assessed. PopPK models were reestablished to develop the model repository. Covariate effects were evaluated and the concentration-time profiles were simulated. An online simulation and calculation tool was developed as an instance.Results: Twelve PopPK models were finally included in the repository. Preterm infants' age and body size, especially the postnatal age and current weight, were identified as the most clinically critical covariates. Simulated blood concentration-time profiles across these models were comparable. Caffeine citrate-dose regimen should be adjusted according to the age and body size of preterm infants. The developed online tool can be used to facilitate clinical decision-making.Conclusions: The first developed repository of PopPK models for caffeine in preterm infants has a wide range of potential applications in the MIPD of caffeine.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"923-938"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy. 接受抗逆转录病毒疗法的艾滋病儿童和青少年的心脏代谢并发症。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-09-01 Epub Date: 2024-08-30 DOI: 10.1080/17425255.2024.2395562

Camilla Muccini, Martina Bottanelli, Antonella Castagna, Vincenzo Spagnuolo

{"title":"Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy.","authors":"Camilla Muccini, Martina Bottanelli, Antonella Castagna, Vincenzo Spagnuolo","doi":"10.1080/17425255.2024.2395562","DOIUrl":"10.1080/17425255.2024.2395562","url":null,"abstract":"Introduction: The course of HIV infection has changed radically with the introduction of antiretroviral therapy (ART), which has significantly reduced mortality and improved quality of life. However, antiretroviral drugs can cause adverse effects, including cardiometabolic complications and diseases, which are among the most common. Compared to the adult population, there are fewer studies in the pediatric population on treatment-related complications. The purpose of this review is to provide an update on the literature regarding cardiometabolic complications and diseases in children and adolescents with HIV.Areas covered: A comprehensive literature review was conducted using PubMed and related bibliographies to provide an overview of the current knowledge of metabolic complications (dyslipidemia, insulin resistance, lipodystrophy, weight gain and liver complications) and diseases (prediabetes/diabetes and cardiovascular diseases) associated with ART in children and adolescents with HIV.Expert opinion: Metabolic complications are conditions that need to be closely monitored in children and adolescents with HIV, as they increase the risk of early development of non-communicable diseases, such as cardiovascular disease. Key areas for improvement include ensuring access to treatment, reducing side effects and improving diagnostic capabilities. Overcoming existing challenges will require collaborative efforts across disciplines, advances in technology, and targeted interventions to address socioeconomic disparities.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"893-905"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation. 用于预防中风的新型 XIa 因子抑制剂 Milvexian：药代动力学和药效学评估。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.1080/17425255.2024.2399721

Alessandro Marè, Arianna Cella, Yan Tereshko, Francesco Toraldo, Gian Luigi Gigli, Mariarosaria Valente, Giovanni Merlino

{"title":"Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation.","authors":"Alessandro Marè, Arianna Cella, Yan Tereshko, Francesco Toraldo, Gian Luigi Gigli, Mariarosaria Valente, Giovanni Merlino","doi":"10.1080/17425255.2024.2399721","DOIUrl":"10.1080/17425255.2024.2399721","url":null,"abstract":"Introduction: Antiplatelets and oral anticoagulants are commonly used to treat patients with various cardiovascular and cerebrovascular diseases. However, the primary concern for clinicians remains the risk of bleeding, thus necessitating the development of new therapies. Milvexian is a new anticoagulant that inhibits factor XIa, preventing the pathological formation of thrombi without increasing bleeding risk.Areas covered: This drug evaluation examines the pharmacokinetic properties of milvexian and provides information on its pharmacodynamics and clinical efficacy in treating some cerebrovascular conditions.Expert opinion: Milvexian shows a good pharmacokinetic profile with low renal elimination rates, justifying its use in patients with a high degree of renal impairment, and without relevant drug-drug interactions. In patients affected by acute non-cardioembolic ischemic stroke or high-risk transient ischemic stroke, milvexian, in addition to dual antiplatelet therapy, seems to have a positive efficacy profile without any safety concerns, especially in terms of intracranial hemorrhage. Two phase 3 trials are ongoing to investigate the efficacy and safety of milvexian for preventing cardioembolic and non-cardioembolic ischemic stroke.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"873-880"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults. 成人体内卡马西平及其代谢物卡马西平-10,11-环氧化物的人群毒物动力学。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 Epub Date: 2024-07-21 DOI: 10.1080/17425255.2024.2381555

Vladan Lukic, Slobodan M Jankovic, Nemanja Z Petrovic, Slavica Vucinic, Jasmina Jovic Stosic, Snezana Djordjevic, Viktorija Dragojevic-Simić

{"title":"Population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults.","authors":"Vladan Lukic, Slobodan M Jankovic, Nemanja Z Petrovic, Slavica Vucinic, Jasmina Jovic Stosic, Snezana Djordjevic, Viktorija Dragojevic-Simić","doi":"10.1080/17425255.2024.2381555","DOIUrl":"10.1080/17425255.2024.2381555","url":null,"abstract":"Background: Carbamazepine is one of the most commonly used antiseizure medications. Although carbamazepine pharmacokinetics in epileptic patients is well described, much less is known about these processes in the patients who experienced self-poisoning episode by this drug. Therefore, the aim of our investigation was to perform population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults.Research design and methods: Software program NONMEM and the ADVAN2 TRANS2 subroutine were used for establishing a population toxicokinetic model for the estimation of clearance and volume of distribution based on of the sum values of carbamazepine and carbamazepine-10,11-epoxide concentrations.Results: Our results indicated that the adult patients' ability to eliminate carbamazepine and carbamazepine-10,11-epoxide following acute carbamazepine self-poisoning was strongly associated with the high levels of CRP and ASP, as well as by the treatment with sedation.Conclusions: Our study should provide better understanding of the toxicokinetics of carbamazepine taken in overdose and better management of patient population admitted to hospital.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"817-825"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0